Literature DB >> 19951907

p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ.

Birgit Terjung1, Jennifer Söhne, Berthold Lechtenberg, Judith Gottwein, Marit Muennich, Volker Herzog, Michael Mähler, Tilman Sauerbruch, Ulrich Spengler.   

Abstract

OBJECTIVE: Autoimmune hepatitis and primary sclerosing cholangitis are chronic inflammatory disorders of unknown aetiology, frequently associated with the presence of perinuclear antineutrophil cytoplasmic antibodies (p-ANCAs) directed against an unknown antigen of myeloid cells. METHODS AND
RESULTS: Here, it is reported that p-ANCAs in autoimmune liver disorders react with beta-tubulin isotype 5 (TBB-5) as autoantigen as well as with its evolutionary bacterial precursor protein FtsZ. Both proteins were confirmed as antigens of p-ANCAs in autoimmune liver disorders by demonstrating reactivity of ANCA-positive sera with recombinant TBB-5 (72-88%) and FtsZ (64-82%) on immunoblots and antigen-specific abrogation of ANCA immunofluorescence when sera had been preabsorbed with tubulin and FtsZ. Using sera from interleukin 10-deficient mice (Il10(-)/(-)), an animal model of inflammatory bowel disease, it was also demonstrated that antibodies against TBB-5 are generated in response to intestinal microorganisms. However, unlike autoimmune liver disorders, human antibodies to FtsZ in the absence of TBB-5 antibodies were also a frequent finding in non-autoimmune liver diseases (up to 95%). Reactivity to TBB-5 without the presence of FtsZ antibodies was found in very few cases (<1%) in autoimmune liver disorders.
CONCLUSIONS: Thus, p-ANCAs in autoimmune liver diseases are directed against human TBB-5 cross-reacting with the bacterial protein FtsZ, probably reflecting an abnormal immune response to intestinal microorganisms in susceptible, possibly genetically predisposed individuals.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19951907     DOI: 10.1136/gut.2008.157818

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  37 in total

Review 1.  Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.

Authors:  Daniel M Chopyk; Arash Grakoui
Journal:  Gastroenterology       Date:  2020-06-20       Impact factor: 22.682

2.  Autoimmune hepatitis and eosinophilic granulomatosis with polyangiitis: a rare association.

Authors:  Saroj Lohani; Salik Nazir; Niranjan Tachamo; Pavani Pagolu
Journal:  BMJ Case Rep       Date:  2017-01-20

3.  Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.

Authors:  Nora Sipeki; Laszlo Davida; Eszter Palyu; Istvan Altorjay; Jolan Harsfalvi; Peter Antal Szalmas; Zoltan Szabo; Gabor Veres; Zakera Shums; Gary L Norman; Peter L Lakatos; Maria Papp
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

Review 4.  Genetics of primary sclerosing cholangitis and pathophysiological implications.

Authors:  Xiaojun Jiang; Tom H Karlsen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-03-15       Impact factor: 46.802

Review 5.  Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.

Authors:  John E Eaton; Jayant A Talwalkar; Konstantinos N Lazaridis; Gregory J Gores; Keith D Lindor
Journal:  Gastroenterology       Date:  2013-07-01       Impact factor: 22.682

Review 6.  Primary sclerosing cholangitis: overview and update.

Authors:  Flavia Mendes; Keith D Lindor
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-12       Impact factor: 46.802

Review 7.  Primary sclerosing cholangitis: diagnosis, prognosis, and management.

Authors:  Siddharth Singh; Jayant A Talwalkar
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-27       Impact factor: 11.382

Review 8.  Mechanisms of tissue injury in autoimmune liver diseases.

Authors:  Evaggelia Liaskou; Gideon M Hirschfield; M Eric Gershwin
Journal:  Semin Immunopathol       Date:  2014-08-01       Impact factor: 9.623

Review 9.  Immune Responses to Intestinal Microbes in Inflammatory Bowel Diseases.

Authors:  Jonathan J Hansen
Journal:  Curr Allergy Asthma Rep       Date:  2015-10       Impact factor: 4.806

Review 10.  Immune dysfunction in cirrhosis.

Authors:  Nora Sipeki; Peter Antal-Szalmas; Peter L Lakatos; Maria Papp
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.